Diphtheria Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Funding
• Alerts
• Clinical Trials
• Forums

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)- β or No Disease Modifying Therapy
Conditions:   Multiple Sclerosis;   Multiple Sclerosis, Relapsing-Remitting Interventions:   Biological: Tetanus, diphtheria, and acellular pertussis vaccine;   Biological: Pneumococcal polysaccharide vaccine;   Biological: Seasonal influenza vaccine Sponsor:   Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 31, 2021 Category: Research Source Type: clinical trials